Litigation Capital Management Limited (AIM:LCM) reported its full year results for the period ending 30 June 2025, highlighting a challenging year marked by case losses, balance sheet strain, and a statutory loss of A$73m. The group concluded 12 investments during the period, achieving six wins and six losses, with a cumulative multiple on invested capital of 1.8x and generating A$50m in revenue. However, adverse outcomes, write-downs on cases under appeal, and conservative fair value adjustments drove a A$100m negative movement, resulting in net assets of approximately 25–30 pence per share post-period end adjustments. Management has implemented decisive steps to streamline operations, cutting operating expenses by up to 50%, refocusing resources on active case management, and prioritising portfolio run-off to reduce net debt of c.A$80m. CEO Patrick Maloney emphasised lessons learned, including reducing concentration risk and applying stricter scrutiny to ongoing investments. Strategic options are under review with Luminous Partners, ranging from debt reduction and portfolio run-off to potential M&A or take-private scenarios. The company was fully exonerated following a Dubai investigation, clearing the way to explore these alternatives. While near-term focus remains on cash preservation and debt reduction, management reiterated confidence in LCM’s 14-year track record, ongoing litigation assets, and the potential enforcement of the Poland/GreenX awards, which could provide material recovery. LCM remains committed to restoring shareholder value, improving operational discipline, and delivering long-term returns through disciplined portfolio management and strategic realignment.

Physiomics PLC (AIM: PYC), the data-driven contract research organisation (CRO), announced strong progress in its financial year ended 30 June 2025, with total income up 46% to £834k and operating losses reduced by 32% year-on-year. Shareholder funds increased to £692k and cash balances rose to £4.6m following a successful £0.9m fundraise, strengthening the balance sheet to support growth initiatives. The Group, which provides quantitative pharmacology, biostatistics, data science, and disease biology expertise to global biopharma clients, expanded beyond oncology into immunology, cardiovascular, and infectious disease. Its consultancy services saw record contract wins, with new business up 63% over the two-year average, a contract conversion rate of 45% versus 27% previously, and over 50% of projects now outside oncology. The recently launched biometrics service line secured its first two contracts worth £110k, creating significant cross-selling opportunities. Physiomics also advanced its personalised dosing software, integrating it into the DoseMeRx platform to gather clinical feedback and progressing its PredicTO clinical trial with Blackpool NHS Trust to calibrate and validate its model. These initiatives support future commercialisation and expanded partnerships. Looking ahead, the company entered FY26 with £654k of contracted income already secured, alongside a strong late-stage pipeline of new opportunities. Management will continue to focus on revenue growth, cost control, operational efficiency, and margin improvement while exploring strategic M&A or partnerships to accelerate scale. With growing demand for model-informed drug development, biometrics, and personalised medicine, Physiomics is positioned in high-growth markets with projected double-digit CAGR across its service areas. Supported by blue-chip client relationships, increasing diversification, and a robust cash position, the Group is confident in delivering sustainable growth, enhanced profitability, and long-term shareholder value.

Harbour Energy PLC (HBR:LSE) delivered a strong half year performance, underpinned by the successful integration of the transformational Wintershall Dea acquisition, which boosted production to over 450,000 barrels per day and strengthened the company’s global portfolio across the UK, Norway, Argentina, and Mexico. Production guidance for 2025 has been raised to 460,000–475,000 boepd, while unit operating costs have been reduced to $13.5/boe, supporting robust operating margins. Harbour reported $0.9 billion in net debt reduction, upgraded free cash flow guidance to $1 billion for 2025, and announced a $100 million share buyback in addition to its $455 million annual dividend, targeting total shareholder returns of $555 million.

Key growth drivers include low-cost, high-margin projects in Norway, unconventional developments in Argentina’s Vaca Muerta basin, and major oil discoveries at Zama and Can in Mexico. Together, these projects underpin 3 billion barrels of 2P reserves and 2C resources, extending reserve life and cash flow visibility well into the next decade. Harbour expects capital expenditure to fall to $1.7–$2.0 billion from 2026, driving margin expansion and supporting $2–$4 billion in cumulative free cash flow between 2025 and 2027.

Despite fiscal challenges in the UK, Harbour remains focused on disciplined capital allocation, portfolio optimisation, and maintaining its investment-grade credit rating. With a diversified, cash-generative production base, significant growth pipeline, and a clear commitment to shareholder returns, Harbour Energy continues to position itself as one of the world’s leading independent oil and gas companies.

Blackbird PLC (AIM: BIRD) has announced its Interim Results, highlighting strong progress in the development of its cloud-based collaborative video editing platform, Elevate. The company remains focused on its product-market fit phase, which runs into 2026, before scaling up globally. Elevate is positioned to disrupt the video editing industry with its professional-grade, browser-based collaboration features designed for entrepreneurs, SMEs, creative teams, and enterprises. Early traction includes over 110,000 sign-ups, nearly 700 paid subscribers, and an 81% increase in user engagement since launch. While churn reduction remains a priority, ongoing feature rollouts—including mobile upload, instant review, and advanced media management—are driving improved retention. Financially, Blackbird reported £0.6m in revenue and achieved positive EBITDA for the first time in H1, supported by disciplined cash management and a £2.1m fundraising. The company sees a vast global addressable market, citing parallels with transformative platforms like Figma and Uber, and believes Elevate could redefine video workflows across industries. Management emphasized its long-term growth strategy, focus on data-driven product development, and disciplined capital allocation to deliver shareholder value. With a strong technology base, an experienced team, and increasing customer adoption, Blackbird positions Elevate as a scalable SaaS platform with significant upside potential for investors as it transitions from product-market fit into its growth phase.

Tissue Regenix Group Plc (AIM: TRX), a global leader in regenerative medicine, announced its Interim Results for H1 2025, reporting a 6% year-on-year revenue decline as softness across core divisions, including a 7% fall in BioRinse and a 4% dip in dCELL, alongside regulatory delays in Certificates to Foreign Governments (CFGs), impacted sales, with released donor tissue revenue down 45%; gross profit margin slipped to 42% due to increased inventory costs and lower production yields, contributing to reduced adjusted EBITDA, although management remains focused on strengthening commercial execution, optimising costs, and restoring growth. Despite these challenges, the Group delivered strategic progress, with direct dCELL revenues up 10%, demineralised bone matrix orders rising 4%, EU patent approval granted for its dCELL process, MDR certification achieved in Europe, and five-year clinical results for OrthoPure XT published in the Journal of Experimental Orthopaedics following shipment of its 1,000th unit, highlighting strong clinical validation. Under new Executive Chairman Jay LeCoque, the Board is implementing a strategic “restart,” prioritising cost base efficiency, enhanced clinical trial investment to drive product adoption, and sharper commercial focus, while targeting geographic expansion into Europe, Asia, and South America through both strategic partnerships and direct distribution channels. With a diversified portfolio spanning allograft and xenograft tissue-based scaffolds across orthopaedics, wound care, and reconstructive surgery, supported by advanced BioRinse and dCELL platforms, Tissue Regenix is positioned to address significant growth opportunities in regenerative medicine. Management confirmed that inventory and cost of goods sold reviews are underway, with outcomes expected by year-end, and reiterated its commitment to safeguarding financial stability, improving EBITDA margins, and delivering sustainable shareholder value. While near-term headwinds persist, including variable donor tissue supply and regulatory uncertainty, the Group remains confident in its long-term strategy, innovation pipeline, and ability to re-establish revenue growth and profitability.

Billington Holdings PLC (AIM: BILN) released its interim results for H1 2025, reporting revenue of £41.8m and profit before tax of £1.7m, reflecting challenging UK and global market conditions and client-led project delays. Despite subdued demand in the structural steelwork sector, the Group increased productive output by 5.4% and maintained resilience through its strong order book, robust balance sheet, and focus on cost optimization. Basic EPS for the period was 9.8p The Group remains debt-free with a significant cash balance of £18.7m, enabling payment of a 25p per share dividend after the period end. Net asset value per share stood at £3.84, highlighting the strength of Billington’s asset-backed position. The ongoing five-year capital investment programme nears completion, with £2.15m spent in the half, including commissioning of a new £1.7m Tubecon facility, positioning the business for future growth in bridge and infrastructure steelwork. Operationally, Billington Structures continues to deliver projects in resilient sectors such as data centres, power, energy-from-waste, food processing, defence, and film studios. Subsidiaries including Peter Marshall Steel Stairs, Hoard-it, Brand-it, Shafton Steel Services, and Specialist Protective Coatings delivered strong performances, while EasyEdge faced softer demand due to sector weakness. Tubecon, although slower to ramp up, now benefits from secured contracts and an encouraging pipeline into 2026.The Group reiterated its commitment to its 5P strategy (People, Properties, Product, Position, Plan), focused on efficiency, margin improvement, ESG performance, and long-term shareholder value creation. Management acknowledged near-term pressure on margins but emphasised that deferred profits will flow through in 2026–27 as delayed contracts mature. With a solid cash position, strong order book extending into 2027, and potential for strategic acquisitions, Billington remains well placed to navigate market challenges and deliver sustainable growth.

Avacta Group plc (AVCT:AIM) delivered its Interim Results Investor Update for the six months ended 30 June 2025, highlighting strong clinical and financial progress. The company advanced its lead program AVA6000 (FAP-doxorubicin) through Phase 1B expansion cohorts, with encouraging early efficacy and safety data in salivary gland cancers and plans to present final Phase 1A data at ESMO 2025. Its second clinical asset, AVA6103 (FAP-exatecan), remains on track to dose first patients in Q1 2026, supported by compelling preclinical results showing durable tumor responses. Avacta also announced a major pipeline update for October 2025, leveraging its proprietary precision platform and Tempest collaboration, which confirmed that 90% of solid tumors express FAP, underlining broad commercial potential.

Financially, Avacta reported cash and equivalents of £12.65m at period end, strengthened by the £8.77m proceeds from the sale of Launch Diagnostics and a £6.5m capital raise used to restructure its convertible bond, reducing the balance to £22.95m by September 2025. Cash outflows from operations were tightly controlled at £12.14m, with additional headroom secured through asset sales and improved financing terms.

Looking ahead, management expects key catalysts including updated AVA6000 efficacy and survival data later in 2025, initial triple-negative breast cancer cohort results in early 2026, and first-in-human dosing for AVA6103 in Q1 2026. The company is actively engaged in strategic partnership discussions to fund late-stage development while maintaining a strong IP position extending into 2045. With a clear growth strategy, advancing pipeline, and increasing industry interest, Avacta positions itself as a pure-play oncology biotech focused on delivering shareholder value and breakthrough cancer therapies.

Northcoders Group PLC (CODE:AIM) delivered its H1 investor update, reporting revenue of £3.7m, a strong gross margin of 67%, and adjusted EBITDA of £0.4m. The Group highlighted a leaner operating model with overheads reduced by 20% and a cash balance of £2.3m, providing stability and no immediate need for fundraising. Consulting arm Counter continues to drive growth, securing contracts with clients including Skipton Building Society, Manchester Airport Group, and a major government department, alongside a newly won £0.5m contract in the software sector. While government funding for training remains uncertain, Northcoders’ Ofsted “Outstanding” rating reinforces its position among the UK’s top providers. Management emphasized a strategic pivot toward Counter’s predictable revenue streams, underpinned by Northcoders’ training engine and alumni network, with a competitive zero-bench model enabling fast, cost-efficient project delivery. The Group is leveraging frameworks such as G-Cloud to expand in both government and private sectors, positioning itself against larger consultancies with a differentiated client partnership approach. With EPS of 0.88p, net assets of £5.4m, and strong cash flows, Northcoders remains well positioned to capitalize on digital transformation, AI-related opportunities, and long-term consulting growth, while continuing to focus on shareholder value creation and disciplined cost management.

Regional REIT Limited (LSE:RGL) delivered its Half Year 2025 investor update, highlighting steady operational progress despite market headwinds. For the six months to 30 June 2025, the Group reported a 1.03% like-for-like decline in net asset value, largely due to unexpected tenant breaks, while maintaining portfolio stability excluding these assets. The company reaffirmed its commitment to a fully covered dividend of 10p per share, supported by earnings per share of 5.2p in H1. Strategic priorities remain focused on debt reduction, portfolio repositioning, and income growth. £23m of disposals have already been completed year-to-date, with a further £40–50m targeted by year-end, driving net LTV toward sub-40%. Capital expenditure of £6m was invested across multiple refurbishment projects, improving EPC ratings and rental yields, with new lettings achieving rents above ERV. Management noted growing tenant demand for high-quality, energy-efficient office space, supported by structural undersupply as new developments stall and older stock is repurposed. ESG initiatives, including solar rollout, EV charging, and energy monitoring, continue to strengthen long-term asset performance. The refinancing of the August 2026 facility remains on track, with manageable cost impacts. The company expressed optimism, citing stabilised yields, improving occupational markets, and strong letting pipelines expected to deliver earnings uplift from 2026. Regional REIT remains focused on delivering long-term value creation through disciplined sales, active asset management, and a resilient dividend policy.

EMV Capital PLC delivered its interim results, highlighting strong progress in assets under management (AUM), portfolio diversification, and its path toward breakeven. Since 2020, AUM has grown from £12m across eight companies to £105m, comprising £38.6m in direct holdings and £66m in third-party managed assets, with a diverse portfolio of 70 companies across deep tech, life sciences, and sustainability. Core revenues covered 79% of operating costs, narrowing core losses to £0.3m versus £0.6m last year, reflecting disciplined cost management and improving margins.